<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19546">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02852434</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-38200</org_study_id>
    <nct_id>NCT02852434</nct_id>
  </id_info>
  <brief_title>Self-administered Lidocaine Gel for Pain-control During Cervical Preparation for Dilation and Evacuation</brief_title>
  <official_title>Self-administered Lidocaine Gel for Pain-control During Cervical Preparation for Dilation and Evacuation: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to compare self-administered lidocaine gel for pain control during cervical
      preparation for dilation and evacuation (D&amp;E) to paracervical block.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain perceived at the time of laminaria or osmotic dilator insertion</measure>
    <time_frame>Intraoperative; Immediately (0-30 seconds) following cervical dilation</time_frame>
    <description>Measured by visual analogue scale (VAS), 0-100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anticipated pain measured by Visual Analogue Scale</measure>
    <time_frame>Preoperative; 30 minutes prior to procedure</time_frame>
    <description>Measured by visual analogue scale (VAS), 0-100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline pain measured by Visual Analogue Scale</measure>
    <time_frame>Immediately prior to procedure</time_frame>
    <description>Measured by visual analogue scale (VAS), 0-100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Speculum Placement measured by Visual Analogue Scale</measure>
    <time_frame>Intraoperative; Immediately following speculum placement</time_frame>
    <description>Measured by visual analogue scale (VAS), 0-100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Pain measured by Visual Analogue Scale</measure>
    <time_frame>Postoperative; Assessed once 10 minutes after procedure</time_frame>
    <description>Measured by visual analogue scale (VAS), 0-100</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Pain Management, Cervical Preparation</condition>
  <arm_group>
    <arm_group_label>Self-administered Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient-administered, vaginal lidocaine gel (2%)--inserted 15 minutes prior to cervical preparation procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paracervical Block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Provider-administered lidocaine (1%) paracervical injection--administered immediately prior to tenaculum placement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine Gel (2%)</intervention_name>
    <arm_group_label>Self-administered Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine Paracervical Block (1%)</intervention_name>
    <arm_group_label>Paracervical Block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women 18 and older

          -  Intrauterine pregnancy â‰¥16 weeks gestation

          -  English speaking competency

          -  Willing and able to sign consent forms

          -  Agree to comply with study procedures

        Exclusion Criteria:

          -  Women less than 18 years of age

          -  IV conscious sedation

          -  Known allergy to study medication (lidocaine)

          -  Any women not meeting inclusion criteria above will be excluded from participation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Principal Investigator, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Administrator, MPH</last_name>
    <phone>650-721-1562</phone>
    <email>familyplanningresearch@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>650-721-1562</phone>
      <email>familyplanningresearch@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 9, 2016</lastchanged_date>
  <firstreceived_date>June 20, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
